Poxel S.A. (EPA:POXEL)
 0.3325
 +0.0225 (7.26%)
  Nov 3, 2025, 5:35 PM CET
Poxel Revenue
In the year 2024, Poxel had annual revenue of 6.64M EUR with 234.98% growth. Poxel had revenue of 5.47M in the half year ending December 31, 2024, with 826.23% growth.
Revenue 
 6.64M
Revenue Growth 
 +234.98%
P/S Ratio 
 2.69
Revenue / Employee 
 1.11M
Employees 
 6
Market Cap 
17.87M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 6.64M | 4.66M | 234.98% | 
| Dec 31, 2023 | 1.98M | 1.31M | 193.92% | 
| Dec 31, 2022 | 674.00K | -12.72M | -94.97% | 
| Dec 31, 2021 | 13.40M | 6.59M | 96.84% | 
| Dec 31, 2020 | 6.81M | -19.75M | -74.37% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| Sanofi | 45.93B | 
| EssilorLuxottica Société anonyme | 27.24B | 
| Eurofins Scientific SE | 7.14B | 
| emeis Société anonyme | 5.77B | 
| Clariane SE | 5.31B | 
| bioMérieux | 4.12B | 
| Ipsen | 3.76B | 
| Sartorius Stedim Biotech | 2.95B | 
Poxel News
- 3 days ago - Appointment of Yves Decadt as Member of Poxel's Board of Directors - Business Wire
 - 18 days ago - Poxel Reports Financial Results for Full Year 2024 and Provides Operational and Financial Update - Business Wire
 - 3 months ago - Following the Filing for the Opening of Reorganization Proceedings, Poxel Announces Changes to Its Corporate Governance - Business Wire
 - 3 months ago - Poxel Provides Update on Negotiations with Creditors and Announces Filing of Reorganization Proceedings, Upcoming Change of Corporate Governance and Suspension of Trading - Business Wire
 - 4 months ago - Poxel Announces Postponement of its Annual General Meeting and Provides a Corporate Update - Business Wire
 - 4 months ago - Poxel SA: New Scientific Presentations by Key Opinion Leaders to Further Highlight the Therapeutic Potential of Imeglimin at ADA 2025, the Leading Diabetes Conference - Business Wire
 - 5 months ago - New Clinical and Scientific Data on TWYMEEG® to be Presented at the 68th Annual Meeting of the Japan Diabetes Society - Benzinga
 - 5 months ago - Poxel Announces Positive Preclinical Data for PXL065 in Hypertrophic Cardiomyopathy To Be Presented at the ESC Congress 2025 - Business Wire